中国药师
中國藥師
중국약사
CHINA PHARMACIST
2015年
8期
1402-1403,1404
,共3页
前列康%非那雄胺%良性前列腺增生
前列康%非那雄胺%良性前列腺增生
전렬강%비나웅알%량성전렬선증생
Qianliekang%Finasteride%Benign prostatic hyperplasia
目的：：比较前列康和非那雄胺治疗大鼠良性前列腺增生的疗效。方法：36只Wistar大鼠随机分成3组,去势14 d后皮下注射丙酸睾丸酮5 mg·kg-1,前列康组按成人剂量10倍剂量灌胃给药,非那雄胺组按0.1 mg·kg-1灌胃给药,对照组给予等量的蒸馏水,21 d后处死,称取前列腺湿质量,量取前列腺体积,光镜观察前列腺组织病理学改变。结果：前列康和非那雄胺组大鼠前列腺湿质量分别为(0.467±0.061)g,(0.408±0.058)g；大鼠前列腺体积分别为(0.371±0.059)ml,(0.365±0.054)ml,均显著低于对照组大鼠(P<0.05)。结论：前列康能显著抑制模型大鼠的良性前列腺增生,其机制可能是通过抑制前列腺细胞的增殖而实现的。
目的：：比較前列康和非那雄胺治療大鼠良性前列腺增生的療效。方法：36隻Wistar大鼠隨機分成3組,去勢14 d後皮下註射丙痠睪汍酮5 mg·kg-1,前列康組按成人劑量10倍劑量灌胃給藥,非那雄胺組按0.1 mg·kg-1灌胃給藥,對照組給予等量的蒸餾水,21 d後處死,稱取前列腺濕質量,量取前列腺體積,光鏡觀察前列腺組織病理學改變。結果：前列康和非那雄胺組大鼠前列腺濕質量分彆為(0.467±0.061)g,(0.408±0.058)g；大鼠前列腺體積分彆為(0.371±0.059)ml,(0.365±0.054)ml,均顯著低于對照組大鼠(P<0.05)。結論：前列康能顯著抑製模型大鼠的良性前列腺增生,其機製可能是通過抑製前列腺細胞的增殖而實現的。
목적：：비교전렬강화비나웅알치료대서량성전렬선증생적료효。방법：36지Wistar대서수궤분성3조,거세14 d후피하주사병산고환동5 mg·kg-1,전렬강조안성인제량10배제량관위급약,비나웅알조안0.1 mg·kg-1관위급약,대조조급여등량적증류수,21 d후처사,칭취전렬선습질량,량취전렬선체적,광경관찰전렬선조직병이학개변。결과：전렬강화비나웅알조대서전렬선습질량분별위(0.467±0.061)g,(0.408±0.058)g；대서전렬선체적분별위(0.371±0.059)ml,(0.365±0.054)ml,균현저저우대조조대서(P<0.05)。결론：전렬강능현저억제모형대서적량성전렬선증생,기궤제가능시통과억제전렬선세포적증식이실현적。
To compare the clinical effect of Qianliekang and finasteride in the treatment of benign prostatic hyperplasia to explore the effectiveness of traditional Chinese medicine for the therapy of benign prostatic hyperplasia. Methods:Totally 36 Wistar rats were selected, and then divided into 3 groups randomly with 12 ones in each, namely Qianliekang group, finasteride group and the control group. After 14 days of castration, the three groups were all treated with subcutaneous injection of 5 mg kg-1 testosterone propi-onate, and Qianliekang group was additionally treated with intragastric administration at 10-fold adult dose, finasteride group was trea-ted with intragastric administration at the dose of 0. 1 mg·kg-1 , and the control group was treated with the same amount of distilled water. The rats were sacrificed after the 21-day treatment, and the wet weight of prostate was determined, the prostate volume was measured and the pathological changes in prostate tissue were observed under a light microscope. Results:The wet weight of prostate in Qianliekang group and finasteride group was (0. 467 ± 0. 061) g and(0. 408 ± 0. 058) g, respectively, the prostate volume was (0. 371 ± 0. 059)ml and(0. 365 ± 0. 054)ml, respectively, and the above indicators were significantly lower than those in the control group(P<0. 05). Conclusion:Qianliekang can effectively inhibit benign prostatic hyperplasia in the model rats, and the mechanism may be related to the proliferation inhibition of prostate cells.
